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The Global Program to Eliminate Lymphatic 
Filariasis (GPELF) was established in 2000 after 
the adoption of a World Health Assembly resolu-
tion in 1997 that called for member states of the 
World Health Organization (WHO) to eliminate 
lymphatic filariasis as a public health problem. 
The condition is caused by one of three filarial 
parasites. Wuchereria bancrofti, the most common 
of the three, causes 90% of lymphatic filariasis 
infections worldwide and is transmitted by several 
genera of mosquitoes — anopheles, aedes, man-
sonia, and culex. The strategy, known as preven-
tive chemotherapy, is annual treatment by means 
of mass drug administration of a two-drug com-
bination of diethylcarbamazine and albendazole 
to all those eligible (with the exclusion of chil-
dren younger than 2 years of age, pregnant 
women, and the very sick) in all countries except 
where onchocerciasis is coendemic (most of Af-
rica and Yemen), in which case a combination of 
ivermectin and albendazole is used (with the ex-
clusion of children shorter than 90 cm, pregnant 
women, and the very sick) because of the poten-
tial side effects of diethylcarbamazine in patients 
with onchocerciasis. The strategy is based on the 
premise that treatments reduce the number of 
microfilarial parasites circulating in the blood 
to a level at which transmission by mosquitoes 
is not sustainable.
Mass drug administration is recommended by 
the WHO to be undertaken for a period of at 
least 5 years with an epidemiologic coverage of 
at least 65% of the total population. Mosquito 
vector control is an important supplemental inter-
vention aimed at breaking transmission. Howev-
er, although mass drug administration has been 
successful in reducing the rate of transmission, 
a considerable number of people remain clini-
cally impaired and have not, to date, benefited 
from the program. The effect of lymphatic fila-
riasis on patients and the social and economic 
effect on caregivers represents the face of what 
was described by the WHO as the world’s second 
most disabling condition; however, this does not 
take into consideration the previously ignored 
burden the condition has on the mental health 
of the patients.1 A package of care that is recom-
mended by the WHO for patients with lymphatic 
filariasis includes surgery for hydrocele, treatment 
for episodes of adenolymphangitis, and manage-
ment of lymphedema to prevent episodes of ade-
nolymphangitis and progression of disease. The 
goal is full geographic coverage of this care 
package to known patients.
To date, the GPELF has made significant prog-
ress using the above strategies to reduce the 
burden of the disease; 6.7 billion treatments 
have been given in 66 countries to more than 
850 million people at least once. In 2016, the WHO 
reported a mass drug-administration coverage 
of 57.9% of the total population that required 
treatment, with 495.6 million persons treated in 
40 reporting countries, and national programs 
that targeted 669.4 million people for treatment 
reported a mass drug-administration coverage 
of 74% in 1996. On the basis of reported results 
of transmission assessment surveys, almost 500 
million persons no longer require treatment. In 
total, 20 countries have stopped mass drug 
administration, including 9 countries that were 
validated as having attained the objectives of the 
program.2 However, despite success, 852 million 
people in 52 countries where infection has not 
been reduced below target thresholds remain in 
need of treatment.
In this issue of the Journal, King and col-
leagues3 report the results of a randomized, con-
trolled trial conducted in Papua New Guinea, in 
which a single dose of a triple combination of 
ivermectin plus diethylcarbamazine plus albenda-
zole was shown to be significantly more effec-
tive in eliminating microfilariae from the blood 
for 3 years than a single dose of the standard 
regimen that has been recommended by the 
WHO to date (which in Papua New Guinea is a 
two-drug regimen of diethylcarbamazine and 
albendazole) and was shown to be similar to the 
two-drug regimen administered once a year for 
3 years. The WHO has recommended that annual 
triple-drug treatment with ivermectin plus diethyl-
carbamazine plus albendazole can be used for 
mass drug administration rather than annual 
treatment with the two-drug regimen of diethyl-
carbamazine plus albendazole in areas where 
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implementation has not started, in areas where 
fewer than four effective rounds of treatment 
with the two-drug regimen have been per-
formed, and in areas where epidemiologic tar-
gets in surveys have not been met and hence 
local transmission might be ongoing.4 The new 
triple-drug treatment, however, is not recom-
mended in areas where onchocerciasis is en-
demic because of the potential adverse effects 
that result from the action of diethylcarbam-
azine against the onchocerca parasite or in areas 
where loiasis is coendemic, also because of the 
potential serious adverse events that are caused 
by the anthelmintic effect of ivermectin in per-
sons with high parasitemia levels of Loa loa.5 
This precludes the use of the triple-drug treat-
ment in many African countries where all three 
filarial parasites are endemic and present a 
public health challenge.6
However, elsewhere, the triple-drug treat-
ment provides significant promise for the elimi-
nation of transmission within a much shorter 
time scale and at less cost. The manufacturers of 
ivermectin have agreed to increase the donation 
of the product, and in August, Samoa became 
the first country to implement the triple-drug 
treatment with the intent of eliminating the in-
fection that has persisted for more than 100 
years.7 The 6.7 billion treatments over the past 
18 years has provided public health benefits 
beyond what was originally envisioned with the 
filariasis program. In addition, the program has 
delivered more broad-spectrum anthelmintic 
drugs than any other deworming program and 
has contributed to wider health benefits that are 
as yet unquantified. Ramaiah and Ottesen8 esti-
mated that 97 million infections, 18 million 
cases of hydrocele, and at least 5.5 million cases 
of lymphedema have been prevented or cured 
during this period. The widespread use of the 
triple-drug treatment will further facilitate the 
public health success of the global filariasis 
elimination efforts, accelerating the reduction of 
transmission, particularly in what have previ-
ously been residual hotspots. It will bring addi-
tional health benefits with the incorporation of 
ivermectin into national programs,9 thus reduc-
ing the transmission of scabies as well as intes-
tinal helminths.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
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